Literature DB >> 15733214

Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man.

Neil Parrott1, Hannah Jones, Nicolas Paquereau, Thierry Lavé.   

Abstract

This paper describes how we are applying physiologically based models of pharmacokinetics as an integrated part in the research and preclinical development of novel drugs. The modeling and simulation tools and techniques used are briefly reviewed and the strategy for application in drug research is described. Three examples illustrate how such models may be applied at different stages ranging from early application prior to in vivo studies, through clinical candidate selection to the estimation of human kinetics and dose selection prior to clinical studies. Although there are obvious restrictions related to limited input data at the earlier stages, the examples illustrate some of the advantages of the approach compared to other more empirical methods. These advantages will be fully exploited with more widespread use of physiological models as powerful and user-friendly software make them accessible to non-specialists.

Entities:  

Mesh:

Year:  2005        PMID: 15733214     DOI: 10.1111/j.1742-7843.2005.pto960308.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  24 in total

1.  BioDMET: a physiologically based pharmacokinetic simulation tool for assessing proposed solutions to complex biological problems.

Authors:  John F Graf; Bernhard J Scholz; Maria I Zavodszky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-10       Impact factor: 2.745

Review 2.  Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Authors:  Jennifer E Sager; Jingjing Yu; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

3.  Model-based drug development: the road to quantitative pharmacology.

Authors:  Liping Zhang; Vikram Sinha; S Thomas Forgue; Sophie Callies; Lan Ni; Richard Peck; Sandra R B Allerheiligen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-13       Impact factor: 2.745

Review 4.  Drug absorption modeling as a tool to define the strategy in clinical formulation development.

Authors:  Martin Kuentz
Journal:  AAPS J       Date:  2008-08-27       Impact factor: 4.009

5.  Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.

Authors:  Tycho Heimbach; Suresh B Lakshminarayana; Wenyu Hu; Handan He
Journal:  AAPS J       Date:  2009-08-26       Impact factor: 4.009

6.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.

Authors:  Agnès Poirier; Anne-Christine Cascais; Christoph Funk; Thierry Lavé
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-20       Impact factor: 2.745

7.  In vivo-in vitro-in silico pharmacokinetic modelling in drug development: current status and future directions.

Authors:  Olavi Pelkonen; Miia Turpeinen; Hannu Raunio
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

8.  Translational considerations for cancer nanomedicine.

Authors:  Stephan T Stern; Jennifer B Hall; Lee L Yu; Laura J Wood; Giulio F Paciotti; Lawrence Tamarkin; Stephen E Long; Scott E McNeil
Journal:  J Control Release       Date:  2010-04-10       Impact factor: 9.776

9.  Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach.

Authors:  Floriane Lignet; Eva Sherbetjian; Nicole Kratochwil; Russell Jones; Claudia Suenderhauf; Michael B Otteneder; Thomas Singer; Neil Parrott
Journal:  Pharm Res       Date:  2016-07-28       Impact factor: 4.200

Review 10.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues.

Authors:  Larryn W Peterson; Charles E McKenna
Journal:  Expert Opin Drug Deliv       Date:  2009-04       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.